CoChat

The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis

Tan, Terrence C. H., Crawford, Darrell H. G., Franklin, Michael E., Jaskowski, Lesley A., Macdonald, Graeme A., Jonsson, Julie R., Watson, Melanie J., Taylor, Paul J., Fletcher, Linda M. · 2012 · Liver International
Cited by 72

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Background: Serum hepcidin concentration is potentially affected by inflammation and iron stores in chronic liver disease (CLD), but little is known about the relationship between hepcidin and the degree of hepatic fibrosis. We investigated the potential role of serum hepcidin as a biomarker of advanced liver disease. Methods: Serum hepcidin was measured in 332 adults with CLD of varying aetiologies, 45 healthy and 50 non‐liver disease patient controls. Liver biopsy data were available for 228 CLD subjects. Results: Hepcidin was decreased in CLD patients compared with non‐liver disease patient controls (P < 0.0001) but not healthy controls, and was lowest in those with cirrhosis (P < 0.0001). Serum hepcidin correlated with hepatic hepcidin mRNA expression in 91 biopsy samples available for genetic analysis (r = 0.68, P < 0.0001). Hepcidin also correlated positively with serum ferritin concentration, transferrin saturation, ALT, serum albumin and haemoglobin, but negatively with serum bilirubin. The hepcidin:ferritin ratio was significantly lower in CLD subjects compared with healthy and disease controls, and decreased with each increase in the stage of fibrosis and siderosis. The hepcidin:ferritin ratio was associated with progressive fibrosis on linear regression, and a value of less than 0.1 was independently associated with cirrhosis on logistic regression analyses (OR 5.54, P < 0.001). Receiver operating characteristic analysis showed the hepcidin:ferritin ratio was able to distinguish between F 0 and F 4 stages of fibrosis (area under receiver operating characteristic curve = 0.86). Conclusions: The hepcidin:ferritin ratio is reduced in relation to increasing fibrosis in CLD and the use of this ratio may have potential future diagnostic implications as a marker of cirrhosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1478-3231.2012.02828.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 72

Metadata

Authors
Tan, T. C. H., Crawford, D. H. G., Franklin, M. E., Jaskowski, L. A., Macdonald, G. A., Jonsson, J. R., Watson, M. J., Taylor, P. J., & Fletcher, L. M.
Venue
Liver International
Publisher
Wiley
Published
2012-06-07
Volume
32
Issue
9
Pages
1391-1399
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
OpenAlex
W2108481106
Cited by
72
References
7
FWCI
4.23
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis. https://app.cochat.ai/papers/10.1111/j.1478-3231.2012.02828.x
The paper
Tan, T. C. H., Crawford, D. H. G., Franklin, M. E., Jaskowski, L. A., Macdonald, G. A., Jonsson, J. R., Watson, M. J., Taylor, P. J., & Fletcher, L. M. (2012). The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis. Liver International. https://doi.org/10.1111/j.1478-3231.2012.02828.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.